Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: A phase III study
Medical Oncology,  Clinical Article

Halim AAF et al. – The objective of this study was to compare concomitant chemoradiotherapy based on weekly low-dose gemcitabine versus weekly low-dose paclitaxel in locally advanced head and neck squamous cell carcinoma. The regimen based on paclitaxel was significantly more tolerable and effective; however, the difference was not enormous.


  • Previously untreated patients with locally advanced squamous cell carcinoma of head and neck randomly assigned to 1 of 2 concomitant chemoradiation regimens: (1) weekly gemcitabine at dose of 100 mg/m2 over 30 min 1–2 h before radiotherapy and (2) weekly paclitaxal at dose of 20 mg/m2 over 60 min 4–6 h before radiotherapy
  • Planned radiotherapy dose 65 Gy over 6.5 weeks in 32 settings
  • 216 patients were randomly divided into 2 groups: group A (110 patients) and group B (106 patients) who received concomitant weekly low-dose gemcitabine and low-dose paclitaxal, respectively, with radiotherapy protocol

  • Hematological toxicity generally mild
  • Non-hematologic toxicities severe
  • Grade III mucositis occurred in 36% in group A and in 24% in group B (P = 0.04)
  • Moreover, grade III dermatitis were encountered in 24% in group A and 13% in group B (P = 0.049)
  • Thirty-two (29%) of group A and 18(17%) of group B patients required enteral or parenteral feeding (P = 0.01)
  • Sixteen (15%) of group A and 6 (6%) of group B required enteral or parenteral feeding that lasted for 6 months (P = 0.03)
  • Regarding late effect on swallowing, 8% of patients in group A and 2% of patients in group B required enteral or parenteral feeding for more than 6 months (P = 0.035)
  • Response rates 78 and 89% in groups A and B (P = 0.038)
  • 2-year PFAS figures 54 and 64% of groups A and B
  • 2-year OS figures 56 and 67%
  • 3-year PFS figures 39 and 48% for groups A and B
  • Both concomitant chemoradiotherapy regimens easily given in outpatient clinic

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List